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Abstracts / Osteoarthritis and Cartilage 22 (2014) S7–S56 S35per cell (um2) (P < 0.01) compared to the control group (6 months old
mice).
Conclusion: These results support the hypothesis that autophagy is
decreased with aging and that compromised autophagy represents a
novel mechanism in the development of OA.
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CARTILAGE INJURY REGULATES NERVE GROWTH FACTOR (NGF) IN
VITRO AND IN VIVO AND DRIVES PAINFUL BEHAVIOUR IN MURINE
OA
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Purpose: Pain is the foremost clinical symptom of osteoarthritis
(OA), however the processes that lead to pain in the joint are poorly
understood. We have previously shown that nerve growth factor
(NGF) is regulated in the joints of mice at the time they get OA-
induced pain and NGF neutralisation is an effective analgesia
(McNamee et al. 2010). In pharmaceutical trials of monoclonal anti
NGF antibodies, clinical efﬁcacy in the treatment of OA pain has
been demonstrated (Lane et al. 2010) but a small minority of
patients developed accelerated disease, raising the possibility that
analgesia per se, or anti-NGF speciﬁcally, contributes to disease
progression. This might occur by removing the mechanical pro-
tection afforded by painful behaviour, or be due to a direct disease
modifying effect of the antibody. The purpose of this study was to
investigate the regulation of NGF in painful murine OA joints, spe-
ciﬁcally focusing on where it is regulated and its induction following
mechanical injury. The dependence of NGF on FGF2, a cytokine
released upon cartilage injury, was also examined. Finally, we
modelled the effects of chronic NGF neutralisation or indomethacin
(a non-steroidal anti-inﬂammatory agent) on disease progression in
murine OA.
Methods: Surgical joint destabilisation, a validated model of OA, was
performed on 10 week old male or female mice and painful
behaviour (a combination of Von Frey, cold plate sensitivity, anal-
gesymeter and Linton incapacitance) assessed weekly. RNA was
isolated from whole knee joints or micro-dissected tissues (articular
cartilage, meniscus and epiphysis). For cartilage injury responses in
vitro, RNA was isolated from hip epiphyses of 5 week old wild type
or FGF2 knockout mice. Additional injury studies were performed on
porcine cartilage that had been pre-incubated with the FGF receptor
inhibitor SB402451. Anti NGF, indomethacin or relevant controls
were administered to wild type OA mice from the time of pain onset
for a further 6 weeks. The analgesic response to anti-NGF was
measured. Joints were sectioned and scored.
Results: NGF was regulated inwhole murine joints at the time the mice
developed pain. When micro-dissected tissues were examined sepa-
rately, NGF was speciﬁcally regulated in the articular cartilage and not
in the bone or meniscus. NGF was strongly regulated (>200 fold) upon
in vitro cartilage injury. In vitro injury-induced NGF was dependent
upon FGF2, as the induction was suppressed when FGF2 knockout
cartilage was explanted, and when porcine cartilage was pre-incubated
with the FGF receptor inhibitor prior to injury. Despite the dependence
of NGF on FGF2 in vitro, FGF2 knockout mice still developed anti-NGF
sensitive pain following joint destabilisation and pain in these mice
occurred earlier than in wild type mice in keeping with their more
severe cartilage injury scores (Chia et al 2009). Neutralising NGF for 6
weeks inmicewith painful OA produced sustained analgesia but did not
alter the severity of cartilage degradation over this time. Similarly,
chronic dosing with indomethacin had no apparent disease modifying
effects.
Conclusions: NGF is a validated pain target in murine OA and is
regulated largely within the articular cartilage in vivo and upon
cartilage injury in vitro. Cartilage injury-induced NGF in vitro was
strongly FGF2 dependent, but this did not seem to be the case in
vivo. Indeed, FGF2 knockout mice developed earlier pain, apparently
correlating with accelerated disease seen in this strain. We were
unable to demonstrate any differences in disease progression
between mice chronically dosed with analgesics and those with pain
over this period of study.52
THERAPEUTIC EFFICACY OF ANTI-ADAMTS5 ANTIBODY IN THE DMM
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R.E. Miller y, P.B. Tran y, S. Ishihara y, J. Larkin z, A.-M. Malfait y. yRush
Univ. Med. Ctr., Chicago, IL, USA; zGlaxoSmithKline, Upper Merion, PA, USA
Purpose: Adamts-5 null mice are protected from cartilage degeneration
and accompanying mechanical allodynia in experimental osteoarthritis
induced by destabilization of the medial meniscus (DMM). A highly
selective and potent monoclonal antibody (Ab) that neutralizes
ADAMTS-5 was able to mimic these ﬁndings when administered pro-
phylactically through 8 weeks post DMM surgery. The goal of the cur-
rent study was to test whether this Ab can provide similar beneﬁcial
effects when administered in a therapeutic setting, i.e., after onset of
joint pathological changes and mechanical allodynia. The therapeutic
effects of anti-ADAMTS-5 on progression of joint damage, mechanical
allodynia in the hindpaw, and concomitant molecular changes in the
nociceptive pathway were analyzed.
Methods: DMM surgery was performed in the right knees of 10-week
old male C57BL/6 mice. Four weeks later, mice were administered
weekly injections of anti-ADAMTS-5 or IgG isotype control Ab (i.p. 10
mg/kg). Untreated mice served as an additional control group. For the
next 12 weeks, mice were monitored bi-weekly for mechanical allo-
dynia in the ipsilateral hind paw using von Frey ﬁbers and the up-down
staircase technique. Sixteen weeks post DMM, mice were taken down
(n¼11-12), and knees were collected for histopathology according to
OARSI recommendations. Total joint score is a sum of cartilage degen-
eration and osteophyte formation on both the lateral and medial sides
of the joint, with a maximum possible score for cartilage degeneration
¼ 60, and osteophyte formation ¼ 6 (max total joint score ¼ 66).
Additionally, subchondral bone sclerosis in the medial compartment
was assessed, using a bone score with a maximum score of 5. In addi-
tion, a set of n¼4 mice/treatment group were taken down 8 weeks after
surgery. Ipsilateral knee innervating dorsal root ganglia (DRG) L3-L5
were harvested, and sensory neurons were isolated and cultured for 4
days. Cell culture supernatants were analyzed for the pro-algesic che-
mokines, MCP-1 and fractalkine, via ELISA.
Results: Histopathology of the knee joint 16 weeks post surgery
revealed that untreated mice developed moderate levels of cartilage
degeneration and osteophyte formation (total joint score ¼ 19.33.1)
and subchondral bone sclerosis (bone score ¼ 2.50.7). When anti-
ADAMTS5 was administered beginning at 4 weeks post DMM, mice
were protected against cartilage degeneration and osteophyte for-
mation (total joint score ¼ 9.52.0) (p¼0.02), but not against sub-
chondral bone changes (bone score ¼ 2.60.3) (p¼0.92) by 16 weeks
post surgery. IgG isotype control Ab afforded some protection against
change in the total joint score, but this was not statistically signiﬁcant
compared to untreated DMM mice (total joint score ¼ 13.13.0)
(p¼0.2). Four weeks after DMM surgery, mice presented with robust
mechanical allodynia in the ipsilateral hind paw, an indicator of sensi-
tization in the pain pathway. In untreated mice and in mice receiving
IgG isotype control Ab, the allodynia was maintained through 16 weeks
post surgery (p<0.0001). In mice treated with anti-ADAMTS-5, the
allodynia resolved and this protection lasted through 12 weeks post
surgery. By 16 weeks post surgery, mechanical allodynia had returned
(p<0.05) (Fig 1). Eight weeks after surgery, innervating DRG neurons
from untreated DMM mice produced elevated levels of MCP-1 and
fractalkine protein compared to naïve and sham mice. When DRG
neurons were cultured from mice treated with anti-ADAMTS5 between
weeks 4 and 8 post DMM, the levels of MCP-1 and fractalkine were
signiﬁcantly downregulated compared to untreated mice (p<0.01). This
downregulation reﬂects decreased activation of sensory neurons and
correlates with decreased mechanical allodynia after treatment with
anti-ADAMTS-5.
Conclusions: This study demonstrates therapeutic efﬁcacy of a potent
and selective anti-ADAMTS-5 Ab in the DMM model, when adminis-
tered in early stages of disease. Therapeutic effect on cartilage degen-
eration, mechanical allodynia as an indicator of pain and concomitant
molecular changes in sensory neurons further supports the idea that
structural joint damage and development of pain are linked. These
studies will help elucidate whether slowing progression of joint dam-
age can prevent or slow the development of pain. Ongoing experiments
are evaluating therapeutic effect of ADAMTS-5 blockade in late stage
experimental osteoarthritis.
